Prognostic significance of <i>FCGR2B</i> expression for the response of DLBCL patients to rituximab or obinutuzumab treatment

Małgorzata Nowicka, Mark S. Cragg, Pedro Farinha et al.|Blood Advances|2021

Cited by 18